Open AccessEpigenetics in prostate cancer treatment
Author(s) -
Katelyn Jones,
Yanquan Zhang,
Yifan Kong,
Elia Farah,
Ruixin Wang,
Chaohao Li,
Xinyi Wang,
ZhuangZhuang Zhang,
Jianlin Wang,
Fengyi Mao,
Xiaoqi Liu,
Jinghui Liu
Publication year - 2021
Publication title -
journal of translational genetics and genomics
Language(s) - Uncategorized
Resource type - Journals
pISSN - 2578-5281
DOI - 10.20517/jtgg.2021.19
Subject(s) - epigenetics , prostate cancer , disease , malignancy , dna methylation , cancer , bioinformatics , histone , medicine , biology , oncology , dna , genetics , gene expression , gene
Prostate cancer (PCa) is the most commonly diagnosed malignancy among men, and the progression of this disease results in fewer treatment options available to clinical patients. It highlights the vital necessity for discovering novel therapeutic approaches and expanding the current understanding of molecular mechanisms. Epigenetic alternations such as DNA methylation models and histone modifications have been associated as key drivers in the development and advancement of PCa. Several studies have been conducted and demonstrated that targeting these epigenetic enzymes or regulatory proteins has been strongly associated with the regulation of cancer cell growth. Due to the success rate of these therapeutic routes in pre-clinical settings, many drugs have now advanced to clinical testing, where efficacy will be measured. This review will discuss the role of epigenetic modifications in PCa development and its function in the progression of the disease to resistant forms and introduce therapeutic strategies that have demonstrated successful results as PCa treatment.